For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased ...

Health and Human Services Secretary Robert F. Kennedy, Jr. doubled down on his support for non-pharmaceutical health ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

SCHOTT Pharma has announced an investment of €100m ($114m) to expand its manufacturing capacity for sterile RTU cartridges.

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

U.K. regulators issued guidance on Thursday, warning weight loss and diabetes medications may weaken the effectiveness of ...

Food scientists at the University of Illinois Urbana-Champaign identified the optimal fermentation conditions for pulses ― the dried ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are medicines that help the body lower blood sugar levels. They work ...

Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Doctors have issued an urgent warning over the 'golden dose' hack for Mounjaro as it could be fatal. According to a recent ...